secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revance Therapeutics, Inc. (—)
CIK:        0001479290
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001479290-24-000099
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revance Q1 product revenue $51.7M (+13% YoY); launches Daxxify for cervical dystonia
--------------------------------------------------------------------------------

- Total net product revenue (DAXXIFY + RHA) $51.7M, up 13% YoY; DAXXIFY net $22.1M after $2M coupon.
- DAXXIFY aesthetic units sold +105% YoY; toxin market share 3.7% (up from 3.0% in Q4).
- Net loss from continuing ops $49.5M, comparable to $48.5M a year ago; cash $277.1M.
- FY 2024 guidance: total net product revenue at least $280M; funded to cash-flow breakeven in 2025.
- Launched DAXXIFY for cervical dystonia (CD), entering $2.7B U.S. therapeutic neurotoxin market; 78% commercial lives covered.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479290/000147929024000099/0001479290-24-000099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479290/000147929024000099/rvnc-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001479290-24-000099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer